Parkinson disease (PD) relates to movement dysfunction [7, [9] [10] [11] . In these 8 investigations, PD subjects are often studied "Off" anti-Parkinson medication (Levodopa 9 replacement). However, the ability of people with PD to imagine movements while "Off" 10 dopamine replacement medication is not well understood. One recent investigation 11 showed that individuals with PD have similar vividness of imagery as healthy adults 12 [12]; however, this study tested the vividness of imagery in people with PD while "On" 13 anti-Parkinson medication. Levodopa has been suggested to normalize brain activity in 14 PD in many regions, including the supplementary motor area (SMA) [13] [14] [15] [16] . This region 15 is associated with motor planning [17, 18] and has been shown to be active during both 16 overt [15] and imagined [4, 7] movements. Therefore, pathological activation of SMA, as 17 well as other regions, may reduce the ability of this group to imagine movement in the 18 "Off" medication state. As imagery studies are often carried out with patients "Off" anti- 19 Parkinson medications, it is important to determine the degree to which people with PD 20 can imagine in this medication state. Further, MI has shown promise as a rehabilitative 21 strategy in both healthy individuals [19] , and recently, those with neurological disorders, 22 specifically stroke [20, 21] . Though The purpose of the current study was to test vividness of MI in individuals with 4 PD both "On" and "Off" anti-Parkinson medications, as well as how vividness of MI in 5 those with PD compares to healthy older adults. Due to the altered activation of brain 6 regions (including the SMA) thought to be associated with motor planning while "Off" 7 anti-Parkinson medication, our primary hypothesis is that individuals with PD "Off" anti-
8
Parkinson medication would exhibit worse vividness of imagery with respect to "On" 9 medication, and that the normalizing effects of Levodopa would result in similar imagery 10 scores between PD "On" and healthy controls. Our secondary hypothesis is that more 11 severe PD symptoms will be associated with worse MI. To assess imagery ability, the Kinesthetic Visual Imagery Questionnaire (KVIQ-8 20) was administered to all subjects in a similar manner to that described in Malouin et 9 al [24] . The KVIQ-20 was chosen as it was designed specifically to be administered to 10 individuals with movement disorders [24] , and has previously been shown to be reliable To assess within-subject side differences, scores were compared across more 9 and less affected sides (PD) and across dominant and non-dominant sides (PD, The KVIQ was administered by one of two trained individuals. Both individuals 1 were trained to administer the exam, and given a script to follow to reduce variance in 2 instruction to participants. For an individual with PD, the "Off" and "On" medication 3 testing sessions were always administered by the same tester. Due to the scripted test 4 administration, as well as the fact that ratings reported by the subject are not open to 5 tester interpretation, we are confident that testing was consistent across testers.
MATERIALS AND METHODS

14
Participants
6 Individuals with PD were tested two times, while healthy controls were tested 7 once. Individuals with PD were first tested "Off" anti-Parkinson medication (>12 hours 8 since last dose; a commonly used criterion used to assess PD symptoms "Off" (Table 1) . Further, no differences were observed between KVIQ-Total in 19 healthy older adults and individuals with PD "On" or "Off" anti-Parkinson medication.
20
Kinesthetic and visual KVIQ components were also not different between PD "On" and 21 controls or PD "Off" and controls. Across all subjects, the visual component of the KVIQ- individuals with PD were slightly higher (better) than those reported in the current study. 13 However, this may be due to the fact that subjects in the current study exhibited more This correlation suggests that ability to imagine may be related to PD motor symptom 7 disease severity. Our investigation included only individuals with mild or moderate PD. 8 Further studies determining ability of individuals with moderate to severe PD are 9 necessary to better understand how PD severity may be related to vividness of imagery. 10 Across all subjects, age was not correlated with MI. This is consistent with a the proportion of individuals who were unable to imagine were similar in control (6/32; 7 19%) and PD groups (5/28; 18%). This is in conjunction with previous reports, which 8 show a small population of both healthy controls [24] and those with PD [12,25] to 9 exhibit poor imagery ability. Subgroup analyses were conducted to determine if subject 10 characteristics in PD (UPDRS, Hoehn and Yahr, disease duration, and age) and 11 controls (age) were different in those exhibiting low imagery scores. In conjunction with 12 correlational analyses described earlier, UPDRS "On" medication was significantly 13 higher (worse) in the group with low imagery scores with respect to others with PD. 14 However, no other differences were observed in those with low KVIQ scores. Due to the 15 similar proportion of poor imaginers in both groups, data from these subjects were not 16 omitted from analysis. These results underscore the importance of assessing imagery 17 ability in all individuals completing a task requiring MI.
18
Limitations
19
In the current study it was not possible to counter-balance the order of testing 20 sessions for individuals with PD. That is, participants with PD were always tested "Off" 21 medication first, then again "On" medication. It is therefore possible that "On" 22 medication scores may have been biased due to a practice effect. If this were the case 23 we may expect an overestimation of imagery vividness on the second administration 1 when "On" medication. Despite the possibility of an overestimation of imagery vividness 2 while "On" medication, we still found no differences between "Off" and "On" medication 3 testing sessions, suggesting that "Off" medication imagery is likely not diminished with 4 respect to imagery in the "On" anti-Parkinson medication state. Though the KVIQ was 5 only administered one time to healthy older adults, the similarity in results from the "On" 
